|4Feb 26, 9:09 PM ET

Basso Tracy 4

Research Summary

AI-generated summary

Updated

Keenova Therapeutics EVP Tracy Basso Receives Award of 34,528 RSUs

What Happened

  • Tracy Basso, EVP & CHRO of Keenova Therapeutics plc, was granted 34,528 restricted stock units (RSUs) on February 25, 2026. The RSUs were granted at $0.00 (no cash paid) and are reported as a derivative award (Form 4 transaction code A).

Key Details

  • Transaction date: 2026-02-25; Form 4 filed: 2026-02-26 (appears timely).
  • Grant size: 34,528 RSUs granted; grant price reported as $0.00.
  • Vesting: RSUs will convert 1-for-1 into ordinary shares upon vesting (F1). They vest ratably on each of the first three anniversaries of February 25, 2027 (likely Feb 25 of 2027, 2028 and 2029) (F2).
  • Adjustment: The total includes 2,303 additional RSUs added due to an adjustment tied to the November 10, 2025 separation of Par Health, Inc. (F3).
  • Shares owned after the transaction: not stated in the provided filing excerpt.
  • Filing note: This Form 4 also serves as the Issuer notice required under Part V of the Companies Act 2014.

Context

  • This was an equity award (not an open-market purchase or sale). RSU grants are a common form of compensation and do not involve an immediate cash outlay; value is realized only if and when RSUs vest and convert to shares.